Who are Angiotensin II Receptor Blockers's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Allisartan Isoproxil, Placebo to Telmisartan, Valsartan+/- Hydrochlorothiazide, losartan/amlodpine, Diovan (Valsartan), Cozzar tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/angiotensin-ii-receptor-blockers.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Angiotensin II Receptor Blockers — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angiotensin II Receptor Blockers (Angiotensin II Receptor Blockers) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II Receptor Blocker (ARB). Area: Cardiovascular.

phase 3 Angiotensin II Receptor Blocker (ARB) AT1 receptor (Angiotensin II Type 1 Receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Angiotensin II Receptor Blockers (Angiotensin II Receptor Blockers) — Ottawa Heart Institute Research Corporation. Angiotensin II Receptor Blockers (ARBs) block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Angiotensin II Receptor Blockers TARGET	Angiotensin II Receptor Blockers	Ottawa Heart Institute Research Corporation	phase 3	Angiotensin II Receptor Blocker (ARB)	AT1 receptor (Angiotensin II Type 1 Receptor)
Allisartan Isoproxil	Allisartan Isoproxil	Guangdong Provincial People's Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Placebo to Telmisartan	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Valsartan+/- Hydrochlorothiazide	Valsartan+/- Hydrochlorothiazide	Novartis	marketed	Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)
losartan/amlodpine	losartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)	Angiotensin II receptors (AT1) and L-type calcium channels
Diovan (Valsartan)	Diovan (Valsartan)	Bayer	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II Receptor Blocker (ARB) class)

Ottawa Heart Institute Research Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Angiotensin II Receptor Blockers — Competitive Intelligence Brief. https://druglandscape.com/ci/angiotensin-ii-receptor-blockers. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab